Topic: patent expirations
AZ put skeptics to rest with a long-promised "return to growth." But it’s still far from its $40B sales goal—and its CEO doubled down on it anyway.
Integration following a large-scale M&A is too much a distraction from Pfizer's "best pipeline in our history," said Bourla.
Acorda faces the prospect of generic competition on its primary revenue source, Ampyra, after an appeals court's decision.
AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.
Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.
Pfizer’s board of directors is providing rich incentives to keep CEO Ian Read on board as the company navigates a host of challenges.